Evidence map›Paper›PMID 34451894›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Maaria Palmroth, Hanna Viskari, Mikko R J Seppänen, Salla Keskitalo, Anniina Virtanen, Markku Varjosalo, Olli Silvennoinen, Pia Isomäki

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Case Report: NovelFrontiers in immunology · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maaria PalmrothMolecular Immunology Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.ORCID 0000-0003-3976-5513
Hanna ViskariDepartment of Internal Medicines, Tampere University Hospital, 33520 Tampere, Finland.
Mikko R J SeppänenRare Disease and Pediatric Research Centers, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
Salla KeskitaloMolecular Systems Biology Group, Institute of Biotechnology, University of Helsinki, 00790 Helsinki, Finland.
Anniina VirtanenMolecular Immunology Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Markku VarjosaloMolecular Systems Biology Group, Institute of Biotechnology, University of Helsinki, 00790 Helsinki, Finland.
Olli SilvennoinenMolecular Immunology Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Pia IsomäkiMolecular Immunology Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Tampere University · FIUniversity of Helsinki · FI

Funding

Academy of Finland 288475 and 294173Academy of Finland N/ACompetitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9U011 and 9X010Doctoral Programme of Medicine and Life Sciences at Tampere University N/AFinnish Cancer Foundation N/AHospital Research Funds, Pediatric Research Center, Helsinki University Hospital N/AInstrumentarium Research Foundation N/AJane ja Aatos Erkon Säätiö N/AMagnus Ehrnroothin Säätiö N/APirkanmaa hospital district competitive research funding N/ASigrid Juséliuksen Säätiö N/ATampereen Tuberkuloosisäätiö N/AUniversity of Helsinki Three-year Research Grant N/A
6 · The paper itself

Abstract

Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is a transcriptional coregulator that has an important role in the regulation of the immune response. IRF2BP2 has been associated with the Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway, but its exact role remains elusive. Here, we identified a novel clinical variant,

Indexed as

inflammationinterferon regulatory factor-2 binding protein-2 (IRF2BP2)interferonsJAK–STAT pathway

Identifiers

PMID34451894
PMCPMC8402006
OpenAlexW3192548667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.